Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
Vaccine. 2024 Feb 27;42(6):1319-1325. doi: 10.1016/j.vaccine.2024.01.056. Epub 2024 Feb 2.
Vaccine. 2024.
PMID: 38310018
Free article.
Clinical Trial.
Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Kuriyama K, Murakami K, Sugiura K, Sakui S, Schuring RP, Mori M.
Kuriyama K, et al. Among authors: sakui s.
Vaccine. 2024 Jan 25;42(3):662-670. doi: 10.1016/j.vaccine.2023.12.036. Epub 2023 Dec 21.
Vaccine. 2024.
PMID: 38129286
Free article.
Clinical Trial.
Item in Clipboard
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
Chiba M, Masumoto K, Kaji T, Matsuura T, Morii M, Fagbemi A, Hill S, Pakarinen MP, Protheroe S, Urs A, Chen ST, Sakui S, Udagawa E, Wada M.
Chiba M, et al. Among authors: sakui s.
J Pediatr Gastroenterol Nutr. 2023 Sep 1;77(3):339-346. doi: 10.1097/MPG.0000000000003867. Epub 2023 Jun 26.
J Pediatr Gastroenterol Nutr. 2023.
PMID: 37364133
Free PMC article.
Clinical Trial.
Item in Clipboard
Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Kuriyama K, Murakami K, Masuda T, Sugiura K, Sakui S, Schuring RP, Mori M.
Kuriyama K, et al. Among authors: sakui s.
Vaccine. 2023 Jun 7;41(25):3763-3771. doi: 10.1016/j.vaccine.2023.05.001. Epub 2023 May 8.
Vaccine. 2023.
PMID: 37198021
Free PMC article.
Item in Clipboard
Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey).
Teramoto T, Ogawa H, Ueshima H, Okada Y, Haze K, Matsui S, Fujikawa K, Hashimoto T, Sakui S, Nishimura K, Kajita M, Horimoto A, Fernandez J.
Teramoto T, et al. Among authors: sakui s.
Expert Opin Drug Saf. 2023 Jan;22(1):81-90. doi: 10.1080/14740338.2022.2094914. Epub 2022 Jul 8.
Expert Opin Drug Saf. 2023.
PMID: 35772177
Clinical Trial.
Item in Clipboard
Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.
Masuda T, Murakami K, Sugiura K, Sakui S, Schuring RP, Mori M.
Masuda T, et al. Among authors: sakui s.
Vaccine. 2022 May 26;40(24):3380-3388. doi: 10.1016/j.vaccine.2022.04.035. Epub 2022 Apr 29.
Vaccine. 2022.
PMID: 35501178
Free PMC article.
Clinical Trial.
Item in Clipboard
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
Masuda T, Murakami K, Sugiura K, Sakui S, Philip Schuring R, Mori M.
Masuda T, et al. Among authors: sakui s.
Vaccine. 2022 Mar 18;40(13):2044-2052. doi: 10.1016/j.vaccine.2022.02.030. Epub 2022 Feb 8.
Vaccine. 2022.
PMID: 35177302
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite